Mangalam Drugs and Organics Ltd's Q4FY25 Quarter Results
- 19 May 2025
Result Summary
- Mangalam Drugs and Organics Ltd reported a 15.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were up by 12.4% QoQ and - - YoY.
- The net profit increased 173.6% QoQ and - - YoY.
- The earnings per share (EPS) of Mangalam Drugs and Organics Ltd stood at 2.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 102.28 | 88.85 | 0.00 | 15.1% | - |
Total Expenses | 98.35 | 87.48 | 0.00 | 12.4% | - |
Profit Before Tax | 3.93 | 1.37 | - | 186.9% | NaN% |
Tax | 0.40 | 0.08 | 0.00 | 400.0% | - |
Profit After Tax | 3.53 | 1.29 | 0.00 | 173.6% | - |
Earnings Per Share | 2.20 | 0.80 | 0.00 | 175.0% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Mangalam Drugs and Organics Ltd is a pharmaceutical company engaged primarily in the manufacturing and sale of pharmaceutical products. The company is recognized in the pharmaceutical industry for its production of active pharmaceutical ingredients (APIs) and formulations. Mangalam Drugs and Organics Ltd caters to both domestic and international markets, providing high-quality drugs that contribute to the healthcare sector. Specific recent developments in the company or changes in its business strategy are not available in the provided data.
Revenue
In the fourth quarter of fiscal year 2025, Mangalam Drugs and Organics Ltd reported a total income of ₹102.28 crores. This represents a quarter-over-quarter increase of 15.1% from the third quarter of fiscal year 2025, where the company recorded a total income of ₹88.85 crores. The year-over-year comparison with Q4FY24 is not available due to the absence of data from that period. The company appears to have experienced substantial revenue growth in the latest quarter, driven by its operations in the pharmaceutical sector.
Profitability
The financial performance of Mangalam Drugs and Organics Ltd in Q4FY25 shows a profit before tax of ₹3.93 crores, which marks a significant increase of 186.9% from Q3FY25's figure of ₹1.37 crores. After accounting for taxes, the profit after tax for Q4FY25 stood at ₹3.53 crores, up 173.6% from the previous quarter's ₹1.29 crores. The tax expense increased by 400.0% quarter-over-quarter, from ₹0.08 crores in Q3FY25 to ₹0.40 crores in Q4FY25. Earnings per share also rose from ₹0.80 in Q3FY25 to ₹2.20 in Q4FY25, indicating a 175.0% increase. The year-over-year comparison is not applicable due to the lack of data for Q4FY24.
Operating Metrics
The company's expenses for Q4FY25 totaled ₹98.35 crores, rising 12.4% from the previous quarter's ₹87.48 crores. Despite the increase in expenses, the company's profitability improved significantly, as reflected in the earnings metrics. The data does not provide specific details on individual operating metrics such as production volumes or cost efficiency measures, but the overall financial figures suggest a positive trajectory in operations. The lack of comparable year-over-year data limits the analysis to quarter-over-quarter observations.